News from the Heart Rhythm SocietyPractice guideline2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Section snippets
2008 Writing Committee Members
Andrew E. Epstein, MD, FACC, FAHA, FHRS, Chair; John P. DiMarco, MD, PhD, FACC, FHRS; Kenneth A. Ellenbogen, MD, FACC, FAHA, FHRS; N.A. Mark Estes III, MD, FACC, FAHA, FHRS; Roger A. Freedman, MD, FACC, FHRS; Leonard S. Gettes, MD, FACC, FAHA; A. Marc Gillinov, MD, FACC, FAHA; Gabriel Gregoratos, MD, FACC, FAHA; Stephen C. Hammill, MD, FACC, FHRS; David L. Hayes, MD, FACC, FAHA, FHRS; Mark A. Hlatky, MD, FACC, FAHA; L. Kristin Newby, MD, FACC, FAHA; Richard L. Page, MD, FACC, FAHA, FHRS; Mark
ACCF/AHA Task Force Members
Jeffrey L. Anderson, MD, FACC, FAHA, Chair; Alice K. Jacobs, MD, FACC, FAHA, Immediate Past Chair; Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect; Nancy M. Albert, PhD, CCNS, CCRN; Mark A. Creager, MD, FACC, FAHA; David DeMets, PhD; Steven M. Ettinger, MD, FACC; Robert A. Guyton, MD, FACC; Judith S. Hochman, MD, FACC, FAHA; Frederick G. Kushner, MD, FACC, FAHA; E. Magnus Ohman, MD, FACC; William Stevenson, MD, FACC, FAHA; Clyde W. Yancy, MD, FACC, FAHA
Table of Contents
Preamble....1738
- 1
Introduction......1740
- 1.1
Methodology and evidence review......1740
- 1.2
Organization of the writing group......1741
- 1.3
Document review and approval......1741
- 1.4
Scope of the focused update......1741
- 1.1
- 2
Indications for pacing......1742
- 2.4
Pacing for hemodynamic indications......1742
- 2.4.1
Cardiac resynchronization therapy......1742
- 2.4.1
- 2.8
Pacemaker follow-up......1746
- 2.8.3
Remote follow-up and monitoring......1746
- 2.8.3
- 2.4
References......1747
Appendix 1. Author Relationships With Industry and Other Entities (Relevant)......1749
Preamble
Keeping pace with the stream of new data and evolving evidence on which guideline recommendations are based is an ongoing challenge to timely development of clinical practice guidelines. In an effort to respond promptly to new evidence, the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Task Force on Practice Guidelines (Task Force) has created a “focused update” process to revise the existing guideline recommendations that are affected by evolving data or
Pacing for Hemodynamic Indications
Although most commonly used to treat or prevent abnormal rhythms, pacing can alter the activation sequence in the paced chambers, influencing regional contractility and hemodynamics. These changes are frequently insignificant clinically but can be beneficial or harmful in some conditions. Pacing to decrease symptoms for patients with obstructive hypertrophic cardiomyopathy is discussed separately in the full-text guideline, Section 2.4.2, “Obstructive Hypertrophic Cardiomyopathy.”
Presidents and Staff
American College of Cardiology Foundation
William A. Zoghbi, MD, FACC, President
Thomas E. Arend, Jr, Esq, CAE, Interim Chief Staff Officer
Charlene May, Senior Director, Science and Clinical Policy
American College of Cardiology Foundation/American Heart Association
Lisa Bradfield, CAE, Director, Science and Clinical Policy
Debjani Mukherjee, MPH, Associate Director, Evidence-Based Medicine
Ezaldeen Ramadhan III, Specialist, Science and Clinical Policy
American Heart Association
Gordon F. Tomaselli,
References (69)
- et al.
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices)
J Am Coll Cardiol
(2008) - et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J Am Coll Cardiol
(2011) - et al.
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies
Heart Rhythm
(2011) - et al.
Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience
Heart Rhythm
(2010) - et al.
Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients
J Am Coll Cardiol
(2008) - et al.
Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy)
J Am Coll Cardiol
(2011) - et al.
HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy
Heart Rhythm
(2010) - et al.
HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations
Heart Rhythm
(2008) - et al.
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms
J Am Coll Cardiol
(2008) - et al.
Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation
J Am Coll Cardiol
(2006)
Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis
Heart Rhythm
Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices
Am J Cardiol
Predictors of response to cardiac resynchronization therapy in patients with a non–left bundle branch block morphology
Am J Cardiol
Significance of QRS complex duration in patients with heart failure
J Am Coll Cardiol
Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)
Lancet
Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances
J Am Coll Cardiol
Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization
Am J Cardiol
Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies
J Am Coll Cardiol
Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study
J Am Coll Cardiol
A new paradigm for physiologic ventricular pacing
J Am Coll Cardiol
Percent right ventricular pacing predicts outcomes in the DAVID trial
Heart Rhythm
Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial
J Am Coll Cardiol
Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee
J Card Fail
Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers
J Am Coll Cardiol
The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts
J Am Coll Cardiol
Methodology Manual and Policies From the ACCF/AHA Task Force on Practice GuidelinesAmerican College of Cardiology Foundation and American Heart Association, Inc
Finding What Works in Health Care: Standards for Systematic Reviews
Clinical Practice Guidelines We Can Trust
Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?Data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry
Circulation
Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD?Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator
Circ Arrhythm Electrophysiol
Implantable cardioverter-defibrillators in tetralogy of Fallot
Circulation
Cardiac resynchronization therapy in paediatric and congenital heart disease patients
Eur Heart J
Cardiac resynchronization in chronic heart failure
N Engl J Med
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
N Engl J Med
Cited by (104)
Prediction of Sudden Death Risk in Patients with Congenital Heart Diseases
2023, Cardiac Electrophysiology ClinicsArtificial intelligence augments detection accuracy of cardiac insertable cardiac monitors: Results from a pilot prospective observational study
2022, Cardiovascular Digital Health Journal2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders
2022, Heart RhythmCitation Excerpt :Nevertheless, while criteria used for determining CRT eligibility have been established through studies conducted in the general population, these approaches may be reasonably implemented in patients with DM1 and DM2.91 While some patients with QRS duration 120–149 ms may also derive benefit from CRT, a QRS duration ≥150 ms is utilized as the evidence for clinical benefit from CRT is strongest for this threshold cutoff.91 Criteria for permanent pacing in patients with symptomatic bradycardia in the general population are similarly applied in DM1 and DM2 patients, despite the lack of published evidence.
This document was approved by the American College of Cardiology Foundation Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee, and the Heart Rhythm Society Board of Trustees in May 2012.
The American College of Cardiology Foundation requests that this document be cited as follows: Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NAM 3rd, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:1297–1313.
This article is copublished in Circulation, Heart Rhythm, and Journal of Thoracic and Cardiovascular Surgery.
Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org), the American Heart Association (my.americanheart.org), and the Heart Rhythm Society (www.hrsonline.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail [email protected].
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier's permission department at [email protected].
Developed in Collaboration With the American Association for Thoracic Surgery, Heart Failure Society of America, and Society of Thoracic Surgeons
- ⁎
Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information.
- †
ACCF/AHA Representative.
- ‡
Heart Rhythm Society Representative.
- §
ACCF/AHA Task Force on Performance Measures Liaison.
- ∥
American Association for Thoracic Surgery Representative.
- ¶
Society of Thoracic Surgeons Representative.
- #
Heart Failure Society of America Representative.
- ⁎⁎
ACCF/AHA Task Force on Practice Guidelines Liaison.